Key result
There is no evidence to support initiating statin therapy in patients with symptomatic New York Heart Association II-IV heart failure, regardless of the cause.
Why the study?
Does statin therapy improve outcomes in patients with symptomatic NYHA II-IV heart failure?
Does statin therapy improve outcomes in patients with symptomatic NYHA II-IV heart failure?
There is no evidence to support initiating statin therapy in patients with symptomatic NYHA II-IV heart failure, regardless of the cause.
Reinforces withholding routine statin initiation in symptomatic NYHA II-IV HF; leaves open targeted trials in milder disease or prevention.
PURPOSE OF REVIEW: To discuss unresolved issues and recent findings regarding the use of statins in heart failure. RECENT FINDINGS: Recent data from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico--Heart Failure and Controlled Rosuvastatin Multinational Trial in Heart Failure suggest that statins did not have any effect on outcome despite significant reduction in low-density lipoprotein and high sensitivity C-reactive protein. SUMMARY: Most of the evidence for the use of statins in heart failure originates from retrospective trials and post-hoc analyses, and is not supported by prospective randomized clinical trials. There is no evidence to support initiating statin therapy in patients with symptomatic New York Heart Association II-IV heart failure, regardless of the cause.
No takes yet. Share an insight, caveat, or question.
Sadek et al. (2009) conducted a review in chronic heart failure. statins was evaluated. There is no evidence to support initiating statin therapy in patients with symptomatic New York Heart Association II-IV heart failure, regardless of the cause.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: